Скачать или смотреть Hims Stock CRASH or BUY? Massive 2026 FDA Update & Price Target Alert

Hims stock (HIMS) has faced an incredibly volatile start to 2026, dropping over 50% following intense regulatory scrutiny from the FDA and a major patent infringement lawsuit from Novo Nordisk. In this video, we break down the latest Q4 earnings beat, the new 2026 revenue guidance of $2.7B-$2.9B, and whether the acquisition of Eucalyptus is enough to save the share price. We also analyze the recent price target cuts from Barclays and Citi to see if HIMS is a value play or a falling knife.

Queries & Topics Covered:
Hims stock price today, HIMS stock analysis 2026, Hims & Hers earnings call, HIMS stock forecast, HIMS vs Novo Nordisk lawsuit, HIMS FDA warning copycat GLP-1, Hims Eucalyptus acquisition news, best telehealth stocks 2026, HIMS price target Barclays, why is HIMS stock falling, Hims & Hers subscriber growth 2026.

Timestamps:
00:00 HIMS Stock Market Crash & 2026 Performance
01:45 FDA Warning & Novo Nordisk Lawsuit Impact
03:50 2026 Revenue Guidance & Eucalyptus Acquisition
05:30 Analyst Price Targets: Buy, Sell, or Hold?

#HIMS #HimsAndHers #StockMarket #Telehealth #Investing #StockAnalysis #GLP1 #FinanceNews2026